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MUHIMBILI UNIVERSITY COLLEGE OF HEALTH SCIENCES 
INFORMED CONSENT FORM 
STUDY TITLE 
The Sickle cell disease (SCD) Study 
THE RESEARCHERS 
Our research team consists of researchers from Muhimbili University College of health 
sciences and Muhimbili National Hospital. This includes doctors, nurses, laboratory 
technologists etc. We also work with researchers from other universities and hospitals 
from all over the world including the London School of Hygiene and Tropical Medicine, 
UK and Kenya. 
PURPOSE OF STUDY 
Sickle cell disease (SCD) is an inherited condition that affects many people in Tanzania. 
As you know some people become very ill with frequent complications and risk of death 
while others remain relatively healthy despite the fact that both have SCD. We need to 
find out why this is so. If we can discover how some people do not have severe disease 
we may be able to use information to make a medicine that we can give to everyone or to 
develop ways to prevent them from developing severe complications of SCD. 
The aim of the study is to describe the spectrum of clinical disease in patients with SCD 
attending and/or admitted to Muhimbili National Hospital (MNH).  This will be the first 
step in trying to understand the causes of illness in SCD in Muhimbili and will focus on 
some areas which are relevant in determining treatment guidelines: malaria, infections, 
nutrition and stroke.  
WHO WILL BE IN THE STUDY 
All patients with proven or suspected SCD who attend the outpatient clinic or who are 
admitted to the paediatric or medical wards at MNH will be told about the study and 
given the option to participate in the study. We will also be asking relatives or people 
without SCD to participate in the study. 
WHAT PARTICIPATION INVOLVES 
For patients with SCD, we will ask you to attend the Haemotology clinic every 3 months 
where a doctor will ask you questions regarding the symptoms of SCD that you have had 
that may or may not have brought you to hospital to seek medical attention. You will also 
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be asked questions about medical problems in the past, demographic, family history etc. 
This is because it is thought that SCD is thought to present with various problems in 
different people and levels of severity is determined by various factors.  You will then be 
examined to determine and document any physical signs and investigations will be taken. 
A blood will also be collected – which is a normal practice for SCD patients attending the 
haematology clinics. In addition, we will also collect a urine sample at each clinic.  
For patients/relatives who are not initially known to have SCD, the same procedures will 
be taken and you will be informed of the results of the tests. If you do not have SCD you 
will not need to attend the haematology clinics. 
WHAT WILL HAPPEN TO THE SAMPLE 
We will take a sample of blood and urine from you or your child to do the tests that 
should be done on all patients attending the hospital, whether or not you are participating 
in the study. These tests will be done in the laboratory at Muhimbili. In addition, there 
will be some special tests that will be done which were not previously done because of 
lack of resources.  
There will be some tests that will also be done as part of the research to improve our 
understanding of SCD. Some of these tests will be done immediately in Muhimbili while 
others will be done in a laboratory outside Tanzania.  
We will also study the genetic material that is in the blood sample, and we would like to 
explain to you what that genetic material is. The genetic material is what makes everyone 
different from birth - in our height, in our looks, and in many other ways, including why 
people have different complications of SCD. We are studying the genetic material from 
some children who are very ill with SCD, and other children who are not ill with SCD, to 
try to discover what part of the genetic material is responsible for this difference.  
There will be some tests that take many years to develop. Therefore we are asking your 
permission to store samples, including genetic material, so that we can perform other 
tests in the future. We are also asking for permission to perform tests on samples which 
had been stored from your previous visits to hospital since your enrolment to the SCD 
study.  
BENEFITS OF THE STUDY 
There will be no direct benefit, financial or otherwise that you will get from this study. 
Your participation in the study will mean that questions about SCD, will help to provide 
answers about SCD. This information will therefore be of use in understanding this 
condition and help to develop medicines and better ways of looking after patients with 
SCD in order to prevent complications, in Tanzania and other places in the world.  
POTENTIAL RISKS OF THE STUDY 
There will be slight pain and discomfort at the site of blood collection. For the blood 
collection we will use equipment that is free of germs and that is made to reduce pain 
during pricking. There will be no new or special drug or treatment that you will receive. 
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If your child has any evidence that suggests increase risk of developing a complication, 
we will discuss the situation with you and we will offer increased frequency of follow up 
to try to prevent this causing any problem in the future.  As new ways are developed to 
prevent these problems they will be discussed with you and offered to your child 
FREEDOM TO PARTICIPATE IN THE STUDY 
We would like to stress that your participation in this study is strictly voluntary - it is 
your decision. Should you decide not to participate; it will not affect the treatment or 
management that you will receive from the hospital. In addition, at any time point during 
the study, decide that you do not wish to participate any further; you are free to end you 
participation, effective immediately. Any such decision will be respected and will not 
influence the quality of health care we will give you or your child.  
If you miss some visits for any reason, but wish to come back into the study or attend the 
clinic, we will be ready to accept you back. 
CONFIDENTIALITY 
All the information that you provide will be confidential. You will be given a code 
number and we will be very careful with the information that we have collected. We will 
make absolutely sure that when we tell people about our findings on the genetic material, 
no-one will be able to discover that this genetic material came from you or your child. 
Only the principal researcher or somebody authorized by him or her will be able to link 
the sample back to each participant.  
Please feel free to ask any questions about the information you have just been given 
or anything else to do with SCD and the care of your child.  
There is more information in the form of leaflets, published papers that is available 
for you to learn more about SCD. Please feel free to take this home with you and 
you can contact us or ask us during your next visit for more information.  
For the study, we will ask you to sign this paper to confirm that you have received 
this information and that you consent to participate in this study.  
In case there is any further information that you require with regard to the study 
please ask to speak to Dr J Makani, Department of Haematology and Blood 
Transfusion, Muhimbili University College of Health Sciences. Tel: 0787 7680688 or 
any of the other investigators. If you ever have questions about your rights as a 
participant, you may call the chairman of the college research and Publications 
Committee, P. O. Box 65001. Tel: 2150302. 
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Informed consent for participants: 
I have read or I have been read the attached information regarding the SCD study in 
English / Swahili (please circle one), a language I speak fluently. I have also had an 
opportunity to discuss the study with the investigators and I am satisfied that I understand 
what the study involves.  
I agree to participate in this study or allow my child / children (listed below) to take part 
in this study:  
(1)_________________________________ 
(2)_________________________________ 
(3)_________________________________ 
(4)_________________________________ 
(5)_________________________________ 
(6)_________________________________ 
Patients/ Parent / Guardian’s  
Signature or thumb print ________________________ Date___________________ 
Parent / Guardian’s Name: _______________________________________________ 
(Please print name) 
Witness  
Signature (if caretaker cannot read)_________________________Date____________ 
Witness’ Name: _______________________________________________ 
(Please print name) 
I certify that the above was explained verbally to the parent/guardian, and that s/he 
understands the nature and the purpose of the study and consents to the 
participation in the study of the above patients.  
I have given them the opportunity to ask questions which have been answered 
satisfactorily.  
Research Officer 
Signature _______________________________________ Date___________________ 
Research Officer Name: _______________________________________________ 
(Please print name) 
